Are clinical trials free? Not entirely. Most trials cover the experimental treatment, safety monitoring, and trial-specific doctor visits, but they usually do not cover routine care, travel, or lost wages. The sponsor pays for the study drug, lab tests run for the trial, and research staff time. Patients still owe for standard care, insurance premiums, and non-medical costs. Medicare and most insurers must cover routine costs in qualifying trials. So the accurate answer is: the research is free, the surrounding care often is not.
The mechanism: why trials are structured to be partly free
Clinical research works on a cost-sponsorship model. A sponsor (a drug company, a university, or a government agency) funds everything that exists only because the trial exists. That includes the investigational drug, the placebo, trial-specific imaging, pharmacokinetic blood draws, and the salaries of research coordinators.
The logic is regulatory and ethical, not charitable. Federal rules require that participants not be charged for the investigational product in most trials, because charging would turn research into a sale. The sponsor must also cover the costs of treating research-related injuries in many cases, though this varies by trial and country. In plain terms: if a test is done for the science, the sponsor pays; if it is done for your health, your insurer may be billed.
That split is enforced through a billing review before the trial opens. Research staff flag every procedure as either "research-only" or "routine care." Research-only items bill to the study account. Routine items bill to the participant's insurance. This document is called a coverage analysis, and it determines who writes the check.
What sponsors typically cover versus what patients pay
The table below reflects the typical structure of an industry- or NIH-funded interventional trial in the United States. Individual trials vary, and the informed consent form must list costs explicitly. Read that document, not the brochure.
| Cost item | Usually covered by sponsor | Usually billed to patient or insurer |
|---|---|---|
| Investigational drug or device | Yes | No |
| Placebo | Yes | No |
| Trial-specific blood tests and imaging | Yes | No |
| Extra clinic visits created by the protocol | Yes | No |
| Research coordinator and staff time | Yes | No |
| Standard-of-care visits (e.g., routine oncology checkups) | No | Insurer or patient |
| Hospitalization for standard treatment | No | Insurer or patient |
| Travel, parking, lodging | Rarely, some trials reimburse | Usually patient |
| Lost wages or childcare | Almost never | Patient |
| Copays and deductibles on routine care | No | Patient |
| Treatment of study-related injury | Often, varies | Sometimes patient |
The bottom rows are where the "free" claim breaks down. A 2018 analysis in JAMA Oncology found that roughly one in five oncology trial participants faced out-of-pocket costs exceeding USD 500, and a minority reported costs above USD 5,000. Travel alone can run USD 1,200 to USD 5,000 per year for patients at distant academic centers.
Who is legally required to pay for routine costs
This is the non-obvious part most explainers skip. The 2010 Affordable Care Act, reinforced by a 2014 Medicare policy, requires Medicare to cover routine patient costs for people enrolled in qualifying clinical trials. That includes items Medicare would normally cover outside the trial. The rule applies to trials of prevention, diagnosis, and treatment of cancer and other life-threatening conditions.
For privately insured patients, coverage depends on state law and the plan. As of 2026, more than 30 states have laws requiring insurers to cover routine costs in cancer trials, but the specifics differ by state. Employer-funded plans are often exempt from state mandates under federal ERISA preemption, so a patient on a self-funded plan may have no legal right to routine-cost coverage.
Medicaid coverage for trial costs is optional for states. Roughly 20 states extend it. Per the 2017 American Society of Clinical Oncology policy statement, financial burden remains a persistent barrier to enrollment, particularly for lower-income patients.
The hidden timeline: when costs actually land
Trial costs are not spread evenly. The expensive phases are screening, the treatment ramp-up, and the follow-up tail. The timeline below shows where money concentrates in a typical 24-month oncology trial.
| Phase | Timing | Typical patient cost exposure |
|---|---|---|
| Pre-screening | Weeks -4 to 0 | Travel for eligibility scans, sometimes not reimbursed |
| Screening | Days 0 to 28 | Mostly sponsor-covered; parking and time off work |
| Treatment cycles | Months 1 to 12 | Routine care copays; travel peaks here |
| Maintenance | Months 12 to 18 | Fewer visits; drug usually still covered |
| End-of-treatment | Month 18 | Final scans, often sponsor-covered |
| Long-term follow-up | Months 18 to 24+ | Sparse visits; insurance handles routine care |
The peak cost period is the treatment phase, when visit frequency is highest. A phase 1 dose-escalation trial can require twice-weekly visits for months, which multiplies travel and time-off costs even when no bill arrives.
Do you get paid to join a clinical trial?
Payment for participation exists but is not the norm for treatment trials. Healthy volunteer phase 1 trials pay stipends, often USD 1,500 to USD 8,000 for multi-week inpatient stays, because they enroll people who are not patients. Treatment trials for sick patients rarely pay, and paying patients raises ethical concerns about undue inducement.
Reimbursement is different from payment. Some trials reimburse travel, parking, and occasionally lodging. Reimbursement is not income and is not taxed in most cases. True payment for participation is taxable. Ask the study team which one applies, because the consent form sometimes uses "compensation" loosely.
Common misconceptions that lead to surprise bills
The most widespread error is assuming "no cost to you" means no cost anywhere. It means the sponsor does not bill you for research procedures. Your insurer can still process claims for routine care.
A second misconception: insurance will automatically pay because the trial is "covered." Coverage requires the trial to meet specific criteria, including that it is federally funded or conducted under an FDA investigational new drug application. A trial run by a private clinic outside those frameworks may not qualify.
A third: patients assume the sponsor covers everything if they are harmed. Injury coverage is often present but limited, and it may not cover lost wages or long-term care. Per 21 CFR 50.25, consent forms must describe whether compensation is available for injury, but they are not required to provide it.
Red flags to examine in any consent form:
- The costs section says "may be covered" instead of listing exact items.
- No named contact for billing questions.
- No statement on who pays for research-related injury.
- Reimbursement terms are described in a separate document not provided upfront.
- The trial requires frequent travel with no travel budget mentioned.
Practical actions before you sign
Do these five things before enrolling. They take about two hours and prevent most financial surprises.
- Request the full cost section of the consent form in writing and read the coverage analysis.
- Call your insurer and ask specifically whether the trial's routine costs are covered, citing the trial's NCT number.
- Ask the study coordinator for the trial's billing contact and the injury-compensation policy.
- Calculate your travel and time-off costs for the full treatment phase, not just the first month.
- Ask whether a social worker or financial navigator is assigned to the trial; many cancer centers provide one.
A written budget beats a verbal reassurance. If the study team cannot produce the cost section, that itself is information.
Limits of the "free" claim and what remains uncertain
Two things are genuinely unclear in this area. First, long-term costs after a trial ends are poorly studied; a patient who finishes a trial may face standard-care bills that were deferred during the study. Second, the actual out-of-pocket burden is under-measured because most trials do not systematically collect patient cost data. The USD 500-plus figure from the 2018 JAMA Oncology analysis is among the few rigorous estimates, and it covers oncology only.
What is established: sponsors cover research procedures, insurers must cover routine costs in many qualifying trials, and patients bear travel, time, and routine copays. What is hypothesis or policy debate: whether broader mandates would increase enrollment, and how much of the enrollment gap is financial versus logistical. The mechanism is clear even where the accounting is not.